Access Denied

Are you a manufacturer, a producer or both? In the second instalment of MedTech Insight's PPWR series, ICON contributors Claudia Anzaldo and Véronique Boscher (Perrin) highlight why medical device companies must first u...

The publication of ICH GCP E6(R3) Annex 2 marks an important step forward for clinical research. In Clinical Trials Arena, ICON's Wendy DeSpain, Global Head of Regulatory Strategy, explains that the most significant imp...

AI-enabled medical devices are entering a new phase. What began as tools for detection and triage is evolving into technology that can help inform diagnosis, treatment decisions and personalised care. As these capabili...

As regulators and HTA bodies place greater emphasis on real-world evidence, the European Health Data Space is creating new opportunities for cross-border research. Discover what EHDS means for study design, data access,...

How can sponsors demonstrate the value of a new cell or gene therapy when highly effective therapies are already established as standard of care? In a new paper published in the Journal of Biopharmaceutical Statistics, ...

The third article in MedTech Insight's PPWR series examines a growing challenge for medical device manufacturers: how to accommodate new packaging labelling requirements on already crowded device packaging. ICON’s Claud...

From advanced analytics to integrated oversight, ICON is redefining how clinical data supports confident decision‑making across the product lifecycle. At SCDM US 2026, meet the ICON team at booth \#308 to learn how we a...

This National Immunisation Awareness Month (#NIAM), discover how ICON's 30+ years of vaccine development experience have supported biotech, pharma, government, and NGO clients in advancing vaccines for some of the world'...

For 20 years, ICON in Poland has been building expertise, supporting innovation and creating career opportunities. Today, we continue to grow. Whether you're looking for the variety and breadth of Full Service or the sp...

The difference between scientific investment and operational investment is a costly gap in neurologic mAb development, but it’s not inevitable. Safety frameworks, site capacity modeling and registry architecture aren't s...

There is no blanket exemption for medtech under the EU's new Packaging and Packaging Waste Regulation. In Medtech Insight, ICON's Claudia Anzaldo and Véronique Boscher (Perrin) explain why manufacturers should start pre...

Successful immunology development requires more than scientific innovation. It requires early and proactive regulatory strategy. As immunotherapies become more sophisticated, development programs must integrate CMC clin...